548 Odcinki

  1. Lessons from Autism on Accelerating Drug Development

    Opublikowany: 24.08.2016
  2. How One Rare Disease Group Leverages Relationships with Industry

    Opublikowany: 17.08.2016
  3. Ice Bucket Challenge Begins to Yield Results

    Opublikowany: 10.08.2016
  4. Why a Common Diabetes Drug May Be Able to Treat a Rare Disease

    Opublikowany: 3.08.2016
  5. How to Improve Patient Access to Experimental Drugs

    Opublikowany: 27.07.2016
  6. Using Social Media to Find Rare Disease Patients for Clinical Trials

    Opublikowany: 20.07.2016
  7. How Rare Disease Patients Weigh Risks and Benefits of a Therapy

    Opublikowany: 13.07.2016
  8. Why Homology Medicines Might Be a Game Changer for Gene Therapy

    Opublikowany: 6.07.2016
  9. Orchard Hopes to Bear the Fruit of Gene Therapy

    Opublikowany: 28.06.2016
  10. Novel Approach to Treat Rare Disease May Lead to Drugs for Common Ones

    Opublikowany: 22.06.2016
  11. Brining Whole Genome Sequencing into the Clinic

    Opublikowany: 15.06.2016
  12. Bringing Patient-Centricity to Clinical Trials

    Opublikowany: 8.06.2016
  13. Determining If a Child's Neurologic or Psychiatric Symptoms are Caused by an Infection

    Opublikowany: 1.06.2016
  14. Making Genetic Data Accessible to Researchers

    Opublikowany: 25.05.2016
  15. How New Sequencing Technology Is Changing Our Understanding of Rare Diseases

    Opublikowany: 18.05.2016
  16. Marathon Readies DMD Drug for FDA

    Opublikowany: 11.05.2016
  17. Searching for Genes They May Protect Against Deadly Diseases

    Opublikowany: 4.05.2016
  18. Helping Patients with the Same Undiagnosed Genetic Condition Find Each Other

    Opublikowany: 27.04.2016
  19. Living with a Disease in Search of a Name

    Opublikowany: 20.04.2016
  20. New Means of Regulating Genes May Hold Promise for Rare Disease Patients

    Opublikowany: 13.04.2016

24 / 28

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Visit the podcast's native language site